U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07828886) titled 'Immune Aging and Advanced Therapy Outcomes in Older Adults With IBD' on Sept. 07.
Brief Summary: The goal of this observational study is to learn whether signs of immune aging and frailty can help predict the balance of benefits and risks of advanced therapies in adults aged 60 years or older with inflammatory bowel disease (IBD) who are starting a new advanced therapy. Treatment will be chosen by the participant's usual clinical team and will not be assigned by the study.
The main questions it aims to answer are:
Are baseline immune-aging and frailty characteristics associated with net clinical benefit at 52 weeks, defined as st...